Ide-cel Appears Active in Almost Three-Fourths of Heavily Pretreated Patients with Myeloma
June 6, 2020
The BCMA-targeting CAR T-cell therapy yielded a response in73% of patients with heavily pretreated relapsed/refractory multiple myeloma.
Recent Content
ASCO Expert Discusses the Use of Autologous Transplantation in Relapsed DLBCL
June 6, 2020
Nirav Niranjan Shah, MD, spoke about the use of autologous stem cell transplant in patients with relapsed, chemosensitive DLBCL during the era of CAR T-cell therapy.
Quiz: When to Use Endoscopy for Acute Upper Gastrointestinal Bleeding
June 5, 2020
In our gastrointestinal cancer quiz, you’ll get a chance to test your knowledge on the use of endoscopy for acute upper gastrointestinal bleeding.
Niraparib-Bevacizumab Combo Improves Clinical Outcomes in Recurrent Ovarian Cancer
June 5, 2020
The combination use of niraparib plus bevacizumab significantly improved clinical outcomes, compared with niraparib alone, in patients with recurrent ovarian cancer.
CC-92480 Plus Dexamethasone Shows Favorable Activity in Relapsed/Refractory Myeloma
June 5, 2020
CC-92480 in combination with dexamethasone demonstrated favorable activity and safety data in patients with heavily pretreated relapsed or refractory multiple myeloma.
Parameswaran Hari, MD, MRCP, Discusses Lenalidomide Maintenance Outcomes in Multiple Myeloma
June 5, 2020
Parameswaran Hari, MD, MRCP, discussed the progression-free survival of patients who stopped versus continued lenalidomide maintenance therapy to treat multiple myeloma from a follow-up trial presented at the 2020 ASCO Virtual Scientific Program.
Andres Poveda, MD, on the Phase III SOLO2/ENGOT-ov21 Final OS Data in Ovarian Cancer
June 4, 2020
Final overall survival results from the trial showed that maintenance olaparib provided an unprecedented improvement in median overall survival versus placebo in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation.
Tucatinib Combination Induces Positive Intracranial Responses in HER2-Positive Breast Cancer Brain Metastases
June 4, 2020
Tucatinib in combination with trastuzumab and capecitabine yielded significant intracranial responses in patients with previously treated HER2-positive metastatic breast cancer and brain metastases.
Neal D. Shore, MD, FACS Discusses Impact, Treatment Implications of the Phase III HERO Trial
June 4, 2020
The Carolina Urologic Research Center expert discusses the benefits of oral relugolix for patients with prostate cancer.
Michael J. Morris, MD on the Impact of PyL-PET/CT Scans on the Clinical Management of Patients With Prostate Cancer
June 4, 2020
An analysis of the secondary endpoint of the phase III CONDOR study showed PSMA scans had a profound impact on patient care.
